Compare KE & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KE | SPRY |
|---|---|---|
| Founded | 1961 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.2M | 558.9M |
| IPO Year | 2014 | 2020 |
| Metric | KE | SPRY |
|---|---|---|
| Price | $26.17 | $4.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $28.00 | ★ $40.00 |
| AVG Volume (30 Days) | 206.6K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 66.18 | N/A |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $1,431,378,000.00 | $84,278,000.00 |
| Revenue This Year | N/A | $87.40 |
| Revenue Next Year | $4.57 | $81.64 |
| P/E Ratio | $22.16 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.60 | $4.91 |
| 52 Week High | $33.19 | $13.15 |
| Indicator | KE | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 53.09 | 34.83 |
| Support Level | $23.42 | $5.04 |
| Resistance Level | $26.85 | $8.61 |
| Average True Range (ATR) | 0.70 | 0.26 |
| MACD | 0.17 | -0.03 |
| Stochastic Oscillator | 83.15 | 3.64 |
Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.